Eureka Therapeutics Announces Publication of Study Demonstrating Broad Anti-Tumor Activity of TCR Mimic-Redirected T Cells Targeting NDC80
06 Jun 2022
AntibodyCell Therapy
June 6, 2022 12:05 UTC
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies to treat solid tumors, today announced the publication of a preclinical study in blood entitled “A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and Hematological Malignancies”. The study was led by Dr. Cheng Liu, President & Chief Executive Officer of Eureka and Dr. Martin Klatt and Dr. David Scheinberg of Memorial Sloan Kettering Cancer CenterCancer Center (MSK).
Chimeric antigen receptor (CAR) T cells represent a novel class of FDA-approved drugs with high efficacy against refractory B cell-derived malignancies. However, target identification and selection for CAR T cell therapy remains challenging as most cell surface proteins are not cancer-specific and therefore often not adaptable for CAR T cell therapy. In contrast, many intracellular proteins are highly tumor-specific and targetable after being presented on the cell surface by human leukocyte antigen (HLA) complexes in the form of peptide-MHC complexes. T cell receptor mimic (TCRm) antibodies can recognize peptide-MHC complexes similarly to TCRs, but with the versatility and applicability of an antibody.
In collaboration with MSK, Eureka scientists used its E-ALPHA® platform to identify TCRm antibodies that target the NDC80-derived complex. NDC80 is an intracellular protein over-expressed in multiple tumor types such as ALL, AML, lymphoma, melanoma, mesothelioma, pancreatic and thyroid cancer. In the study, anti-NDC80 TCRm-redirected T cells demonstrated high specificity in recognizing and killing multiple cancer cell lines. Moreover, no toxicities to healthy leukocytes and hematopoietic stem cells were observed.
“TCR mimic antibodies can unlock the potential of T-cell therapies by targeting intracellular proteins that are presently not druggable by conventional antibodies or conventional CAR-T cells that target cell surface proteins,” said Dr. Cheng Liu, Founder and CEO, Eureka Therapeutics. “We are excited by the study and look forward to seeing the expanded use of TCR mimic antibodies in other cancer types.”
About Eureka Therapeutics
Eureka Therapeutics, Inc. is a privately-held clinical-stage biotechnology company focusing on developing novel T cell therapies to treat cancers. Its core technology centers around its proprietary ARTEMIS® cell receptor platform and E-ALPHA® antibody discovery platform for the discovery and development of potentially safer and more effective T cell therapies for the treatment of solid tumors and hematologic malignancies. The Company currently has two clinical programs, ET140203 (ARYA1 and ARYA2) and ECT204 (ARYA3), in Phase I/II US trials in patients with advanced liver cancer.
Eureka Therapeutics, Inc. is headquartered in the San Francisco Bay Area. For more information on Eureka, please visit .
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.